Trials / Completed
CompletedNCT03317574
MEDITOXIN® in Treatment of Crow's Feet Line
A Randomized, Double-blind, Active Drug Controlled, Multi-center, Phase Ⅰ/Ⅲ Study to Determine the Efficacy and Safety of Meditoxin® in Treatment of Crow's Feet Line
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | botulinum toxin type A | 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas |
| DRUG | botulinum toxin type A | 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas |
Timeline
- Start date
- 2017-08-17
- Primary completion
- 2017-12-01
- Completion
- 2018-05-14
- First posted
- 2017-10-23
- Last updated
- 2019-03-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03317574. Inclusion in this directory is not an endorsement.